Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels.
about
A systems approach for tumor pharmacokineticsMechanistic and quantitative insight into cell surface targeted molecular imaging agent design.EGFR-expression in primary urinary bladder cancer and corresponding metastases and the relation to HER2-expression. On the possibility to target these receptors with radionuclides.Functionalized polymeric nanoparticles loaded with indocyanine green as theranostic materials for targeted molecular near infrared fluorescence imaging and photothermal destruction of ovarian cancer cells.Affibody-mediated PET imaging of HER3 expression in malignant tumours.Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET/CT.Erythrocyte-derived nano-probes functionalized with antibodies for targeted near infrared fluorescence imaging of cancer cells.Radionuclide imaging of drug delivery for patient selection in targeted therapy.Dual-Nuclide Radiopharmaceuticals for Positron Emission Tomography Based Dosimetry in Radiotherapy.Imaging of HER3-expressing xenografts in mice using a (99m)Tc(CO) 3-HEHEHE-Z HER3:08699 affibody molecule.Direct comparison of 111In-labelled two-helix and three-helix Affibody molecules for in vivo molecular imaging.Comparative Evaluation of Anti-HER2 Affibody Molecules Labeled with 64Cu Using NOTA and NODAGA.Development of an optimal imaging strategy for selection of patients for affibody-based PNA-mediated radionuclide therapy.
P2860
Q28477077-9580FCB6-8212-4AB0-944C-E41A6B040AC3Q30383551-E8CE7E5B-A08D-49DF-B577-E419D9A424E5Q35184816-EDF7A136-8927-486E-ADD6-2EBE7F509C6FQ35194188-D071A967-CDA3-4B29-AE4E-E4285B297F7DQ36174716-FB72EB84-470E-4B35-93E6-7532401FAA1FQ36510875-A0A2A1F4-D139-48D6-9CB3-8AB94EEA9F74Q37057611-FDC79A3E-9B98-43CC-9058-F9D89056D8BCQ38176652-E390F141-08EC-4F0E-BDF6-EDEBE9B240F7Q38612027-7829A80A-2E49-4AAF-B020-68ABDE529952Q39016180-454F61C2-5A9A-45B0-BC3D-D3DD2B20EE6EQ39428462-A45FA683-5551-446B-92F5-6FCAC2A9796AQ43376047-A4FC8B59-8FE7-453D-9D83-A4E28580EE66Q55441941-8B89CCFF-4145-4E5D-950C-7941CAE8771C
P2860
Optimal specific radioactivity of anti-HER2 Affibody molecules enables discrimination between xenografts with high and low HER2 expression levels.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Optimal specific radioactivity ...... nd low HER2 expression levels.
@en
Optimal specific radioactivity ...... nd low HER2 expression levels.
@nl
type
label
Optimal specific radioactivity ...... nd low HER2 expression levels.
@en
Optimal specific radioactivity ...... nd low HER2 expression levels.
@nl
prefLabel
Optimal specific radioactivity ...... nd low HER2 expression levels.
@en
Optimal specific radioactivity ...... nd low HER2 expression levels.
@nl
P2093
P2860
P1476
Optimal specific radioactivity ...... and low HER2 expression levels
@en
P2093
Anders Wennborg
Helena Wållberg
Mattias Sandström
Monika Hansson
P2860
P2888
P304
P356
10.1007/S00259-010-1646-3
P577
2010-11-11T00:00:00Z